Singapore, Jan. 15 -- Australia-based AdAlta Limited, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.

This partnership marks the official launch of AdCella's "East to West" strategy, leveraging Chinese innovation and Australian expertise to accelerate global access to next-generation cell therapies.

Published by HT Digital Content Services with permission from BioSpectrum Asia....